Chronic Myeloid Leukemia (CML) Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

The report titled “Chronic Myeloid Leukemia (CML) Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2021-2029” provides detailed intelligence about the chronic myeloid leukemia (CML) treatment market. The report includes detailed analysis on market dynamics, market estimation and forecast for the period of 2021 to 2029. The report segments market on the basis of drug type and geographies. The report also covers the impact of covid 19 on the growth and revenues of the CML treatment market. The pandemic has significant impact on the diagnosis of CML. Healthcare services were limited only to emergency cases and this significantly limited the number of patients that visited the healthcare institutes.

Chronic Myeloid Leukemia affects the white blood cells known as myeloid cells. It is caused by spontaneous mutation of chromosome. CML progresses slowly and typically affects the aged. About 15% leukemias in adults are CML. Over 8450 people in the U.S. were diagnosed with CML in 2021. The average age of diagnosis is 64 years. While the number of patients that were diagnosed by CML increased by 2 % in the U.S. in comparison to 2007 to 2016, the number of people who died reduced by 1% during the same period. About 1130 deaths occurred due to CML in the U.S. 

There has been a significant advance in the CML treatment regime in the last two decades. There has been significant increase in number of new drugs approvals for CML treatment. New drug class that has transformed the treatment of CML includes tyrosine kinases (TKIs) or BCR-ABL inhibitors. They are crucial element in CML treatment. First generation imatinib and more efficient second generation BCR-ABL inhibitor nilotinib and dasatinib, with ponatinib and bosutinib have been approved for commercialization. Some studies identified that nilotinib and dasantinib were more effective han imatinib in first line chronic phase CML. This offered better results and a better and rapid response.

The report segments the market based on geographic segmentation that includes North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. These key regions are further segmented by countries including U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC. The key market determinants, key development, new drug approvals and pipeline, market estimates and revenues for the year 2021 to 2029 and forecast year 2021 to 2029 is included in the report for every geographic region. The key companies covered in the report are Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., ARIAD Pharmaceuticals, Inc., Pfizer, Inc., Hospira, Inc., Prism Pharmaceuticals, Incyte Corporation, Bio-Path Holdings, Stragen Pharma SA, Otsuka Pharmaceutical Co., Ltd. and others. Profiling and key developments have been covered in the report. 

Based on the type of treatment, the global chronic myeloid leukemia (CML) treatment market is segmented as follows:

• Targeted Therapy
• Imatinib
• Dasatinib
• Nilotinib
• Bosutinib
• Ponatinib
• Chemotherapy
• Radiation Therapy
• Splenectomy
• Stem Cell Transplant 

As per American Cancer Society, ongoing myeloid leukemia (CML) cells contain an oncogene, BCR-ABL, that isn't identified in normal cells. These qualities have a capacity to make a protein, BCR-ABL, which makes CML cells develop and reproduce at a very rapid rate. BCR-ABL is a kind of protein known as a tyrosine kinase. Medications known as tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the typical treatment for CML. Clinical professionals propose that, the BCR-ABL protein inhibits cell apoptosis and DNA fix, prompting genomic instability and further hereditary irregularities. Prior to imatinib, a novel targeted therapy oncologists recommended stem cell therapy for treatment of CML. The medications that were accessible prior were not very effective and less than 50% of patients could survive more than 5 years of diagnosis. Such advanced novel drugs such as imatinib now remain as a standard treatment, and stem cell transplants are not used in priority like before. Stem cell transplant is looked as a possibility for young patients and for patients who are resistant to TKI. Targeted therapy contributed highest to the market revenues for CML treatments market in 2021. The key driver included increasing level of efficiency with newer drug options, supporting insurance framework, increasing awareness among patients for early diagnosis and targeted therapy. 

For the purpose of this study, the global chronic myeloid leukemia (CML) market is categorized into:

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA) 

North America was the market leader for CML treatment market in 2021. The key determinants were high awareness leading to early diagnosis, well-developed healthcare setup and supportive reimbursement scenario, rapid drug approval, and accessibility to novel targeted drug therapies. Of the total patients of 8450 who were diagnosed in 2021, 4,970 were men and 3,480 were women. Out of 1130 deaths in 2020, 670 were men and 460 were women. There has been significant development in CML treatment regime in the last decade. For instance in 2012 USFDA approved 3 drugs including bosutinib, ponatinib, and omacetaxine. Similarly in 2013 three more key drugs were approved namely ponatinib, omacetaxin, and bosutinib. The key challenge to receive treatment is the affordability of drugs. The prices are significantly high and this limits the accessibility to high-priced drugs in developing economies. Therefore this limits the growth of CML treatment. However, newer drugs approvals and government initiatives to make treatment affordable, the emergence of crowdfunding for treatment is expected to boost the market growth during the forecast period on 2021 to 2029.


This product will be delivered within 2 business days.